Phase 2 Leukaemia Trial, Recruiting (NCT06299462)

Phase 2 Leukaemia Trial, Recruiting NCT06299462 Sponsor: Instituto Nacional de Cancer, Brazil Condition: Leukaemia

Printed from Voxsanity (voxsanity.com.au) — NCT06299462 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Leukaemia

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with acute leukemia that is currently in first or second remission, a bone marrow condition called myelodysplasia with fewer than 20% abnormal cells (blasts), or Hodgkin's or non-Hodgkin's lymphoma that has partially responded to rescue (salvage) treatment
People who are scheduled to receive a stem cell transplant from a related or unrelated donor whose tissue type is a close match (HLA-compatible)
People who are considered suitable for a stem cell transplant using one of several specific preparatory treatment combinations given before the transplant (confirm exact combinations with trial site)
People whose stem cells will be collected from the bloodstream (peripheral blood) rather than directly from the bone marrow
People aged between 18 and 60 years

Who may not be able to join:

People who have liver problems, specifically where liver enzyme levels (transaminases) are more than twice the normal range

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Leonardo J Arcuri, MD, PhD, Instituto Nacional de Cancer

Phone: +5521981334715

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06299462

Sponsor: Instituto Nacional de Cancer, Brazil

Phase: Phase 2

Status: Recruiting

Condition: Leukaemia

Trial contact: +5521981334715

More information: https://clinicaltrials.gov/study/NCT06299462

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with acute leukemia that is currently in first or second remission, a bone marrow condition called myelodysplasia with fewer than 20% abnormal cells (blasts), or Hodgkin's or non-Hodgkin's lymphoma that has partially responded to rescue (salvage) treatment
People who are scheduled to receive a stem cell transplant from a related or unrelated donor whose tissue type is a close match (HLA-compatible)
People who are considered suitable for a stem cell transplant using one of several specific preparatory treatment combinations given before the transplant (confirm exact combinations with trial site)
People whose stem cells will be collected from the bloodstream (peripheral blood) rather than directly from the bone marrow
People aged between 18 and 60 years

Who may not be able to join:

People who have liver problems, specifically where liver enzyme levels (transaminases) are more than twice the normal range

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Instituto Nacional de Cancer, Brazil

Registry

ClinicalTrials.gov

Start date

14 June 2024

Est. completion

1 June 2031

Where this trial is recruiting

🇧🇷 Brazil

Primary endpoints

Cumulative incidence of grades III-IV acute GVHD by the MAGIC criteria

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov